For research use only. Not for therapeutic Use.
Atinvicitinib is a kind of pyrazole compound. Atinvicitinib has the potential for the research of atopic dermatitis (extracted from patent WO2021123094A1)[1].
| Catalog Number | I045121 |
| CAS Number | 2169273-59-8 |
| Synonyms | 1-[(3R,4S)-4-cyanooxan-3-yl]-3-[(2-fluoro-6-methoxypyridin-4-yl)amino]pyrazole-4-carboxamide |
| Molecular Formula | C16H17FN6O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C16H17FN6O3/c1-25-14-5-10(4-13(17)21-14)20-16-11(15(19)24)7-23(22-16)12-8-26-3-2-9(12)6-18/h4-5,7,9,12H,2-3,8H2,1H3,(H2,19,24)(H,20,21,22)/t9-,12+/m1/s1 |
| InChIKey | PRQMBGDYXWVEHE-SKDRFNHKSA-N |
| SMILES | COC1=NC(=CC(=C1)NC2=NN(C=C2C(=O)N)C3COCCC3C#N)F |
| Reference | [1]. Mohamad Morsey, et al. Bispecific caninized antibodies and bispecific binding partners for treating atopic dermatitis. Patent WO2021123094A1. |
